FDA finds deficiencies in AMDL's application
This article was originally published in Clinica
Executive Summary
Cancer test manufacturer AMDL has suffered a setback in its bid to sell in the US its DR-70 kit as an aid in monitoring patients with colorectal cancer, after the FDA identified deficiencies in the firm's marketing application.